Form 8-K - Current report:
SEC Accession No. 0001493152-25-007865
Filing Date
2025-02-21
Accepted
2025-02-21 16:05:31
Documents
14
Period of Report
2025-02-19
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 41346
  Complete submission text file 0001493152-25-007865.txt   257742

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE lixt-20250219.xsd EX-101.SCH 3519
3 XBRL DEFINITION FILE lixt-20250219_def.xml EX-101.DEF 26564
4 XBRL LABEL FILE lixt-20250219_lab.xml EX-101.LAB 36548
5 XBRL PRESENTATION FILE lixt-20250219_pre.xml EX-101.PRE 25188
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5517
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 25651698
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)